Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Avita Medical (TASE:BLWV), Inc. (NASDAQ:RCEL) reported Monday it has entered into a placement agreement with MST Financial Services Pty Limited for the sale of 17,201,886 CHESS Depositary Interests (CDIs) to Australian institutional and professional investors. The CDIs will be issued at approximately AU$1.32 per CDI, with five CDIs representing one share of common stock. The company, currently trading at $5.55, has seen its stock decline over 56% year-to-date, with InvestingPro data showing significant cash burn and short-term liquidity challenges.
The company expects to receive gross proceeds of about US$15 million (A$22.7 million) from the placement. Placement agent fees totaling approximately US$0.8 million will be paid in a combination of cash and CDIs. The transaction is expected to close on or about August 19. Despite recent challenges, the company maintains a strong gross profit margin of 84% and has achieved 38% revenue growth over the last twelve months. Get deeper insights into Avita Medical’s financial health and access exclusive analysis through InvestingPro, which offers comprehensive research reports and real-time metrics for over 1,400 US stocks.
According to the company’s statement in the SEC filing, the CDIs to be issued in this placement will be exempt from registration under the Securities Act of 1933, relying on Regulation S for offerings made outside the United States. Securities issued under this exemption will carry legends or notices in accordance with Regulation S requirements.
This information is based on a press release statement included in Avita Medical’s recent SEC filing.
In other recent news, Avita Medical Ltd . reported its Q2 2025 earnings, showing a net loss of $0.38 per share, which was larger than analysts’ expectations of a $0.25 loss. The company experienced a 21% year-over-year increase in commercial revenue, reaching $18.4 million, but still fell short of the anticipated $22.51 million. In addition to the earnings report, Lake Street Capital Markets has assumed coverage of Avita Medical with a Buy rating and set a price target of $8.00. The research firm highlighted that Medicare Administrative Contractor adjudications began in July, and broader compliance is expected in the second half of 2025. This suggests that the reimbursement issues affecting the company’s first-half performance are on track for resolution. These developments provide important insights for investors tracking Avita Medical’s progress and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.